Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

NCT02579603 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

DRUG: Nintedanib
DRUG: Pirfenidone

Sponsor

Boehringer Ingelheim